MNPRMonopar Therapeutics Inc.
What is the market doing?
Rangebound. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Choppy, but holding above its 200-day average. Oversold (RSI 26). Price is +9% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How MNPR is trading
Monopar Therapeutics Inc. is −15% over the past year while the S&P 500 is +18%: 33 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +9.1%
vs 200-day average · close to trend
- RSI (14)
- 26
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 33%
Below its 52-week high
Details›
- Last close2026-10-08
- $83.72
- 1 monthS&P 500 +1.6%
- −25%
- 1 yearS&P 500 +18%
- −15%
- 5 yearsS&P 500 +86%
- +244%
- vs 50-day average$104.86
- −20%
- 52-week high
- $124.25
- 52-week low
- $50.12
- Annualised volatility
- 439%
| Year | Return |
|---|---|
| 2026 (year to date) | +28% |
| 2025 | +197% |
| 2024 | +1194% |
| 2023 | −86% |
| 2022 | −26% |
| 2021 | −48% |
| 2020 | −63% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 3 of 7 | +23% |
| Feb | 7 | 2 of 7 | +9.0% |
| Mar | 7 | 1 of 7 | −18% |
| Apr | 7 | 2 of 7 | −3.3% |
| May | 7 | 2 of 7 | −3.8% |
| Jun | 7 | 5 of 7 | +9.9% |
| Jul | 7 | 2 of 7 | −1.7% |
| Aug | 7 | 1 of 7 | −13% |
| Sep | 7 | 2 of 7 | +37% |
| Oct | 7 | 4 of 7 | +20% |
| Nov | 6 | 4 of 6 | +4.7% |
| Dec | 6 | 2 of 6 | −3.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.